Navigation Links
NxStage Announces CE Mark Approval for New High Flow Capabilities with System One
Date:2/21/2013

p>About NxStage Medical Inc.
NxStage is a medical device company, headquartered in Lawrence, MA, USA, which develops, manufactures, and markets innovative systems for the treatment of end-stage renal disease (ESRD), and acute kidney failure. The System One home hemodialysis device developed by NxStage is the only FDA approved portable hemodialysis machine cleared for home use. For more information on NxStage, or NxStage products, visit, http://www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: NxStage Medical, Inc., ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NxStage Announces CE Mark Approval for Nocturnal Home Hemodialysis
2. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
3. NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th
4. Robert Funari Joins NxStage Board of Directors
5. NxStage Announces Fourth Quarter 2012 Investor Conference Schedule
6. NxStage Reports Record Revenue for the Third Quarter of Fiscal 2012
7. NxStage Names Todd M. Snell Senior Vice President of Quality Assurance, Regulatory & Clinical Affairs
8. NxStage Submits Formal Comments to CMS to Improve Patient Access to Life-changing More Frequent Home Hemodialysis Therapy
9. NxStage Patient and Advocate Brian Hess Receives Prestigious Honor from American Association of Kidney Patients
10. NxStage to Present at the Canaccord Genuity 32nd Annual Growth Conference
11. NxStage Reports Record Revenue For The Second Quarter Of Fiscal 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... the leading health care supply chain expertise, analytics and ... national contracts that expand its portfolio to provide hospital ... These include manufacturer product and service agreements, as well ... IT consulting support. New Novation agreements ...
(Date:1/15/2014)... 2014 Shire plc (LSE: SHP, NASDAQ: ... Trading (OFT) approval condition to the announced tender offer for all ... As a result of the waiver, the transaction is no ... tender offer on January 24, 2014 following the currently scheduled expiration ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... 11, 2011 Conatus Pharmaceuticals Inc. today announced the ... private placement financing.  This financing was led by new ... participation by existing investors; Aberdare Ventures, Advent Venture Partners, ... Fund.  Conatus will use the proceeds to advance the ...
... 2011 Stryker Corporation,s (NYSE: SYK ) ... 510(k) clearance for its MDM X3 Modular Dual Mobility ... to the company,s portfolio of next-generation technologies designed to ... and address a broader patient population, including both primary ...
Cached Medicine Technology:Conatus Pharmaceuticals Completes $20 Million Series B Private Placement Financing 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 2Stryker Receives FDA 510(k) Clearance to Market Modular Dual Mobility Acetabular (Hip) System 3
(Date:4/17/2014)... LSTM have called for more research to be ... children in sub-Saharan Africa. In a paper in ... Russell Stothard, working with colleagues in the department ... University, in Cleveland Ohio, University of Cambridge and ... into the joint burden of HIV/AIDS and schistosomiasis ...
(Date:4/16/2014)... NJ (April 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: ... 1 study of CDX-1401 in solid tumors, including long-term ... Medicine (Vol 6 Issue 232). The data demonstrate ... clinical benefit in patients with very advanced cancers and ...
(Date:4/16/2014)... While it is well known that fertility treatments are ... that multiples are at elevated risk of premature birth, ... Fertility and Sterility . The article ... reduce the odds of multiple births and prematurity, including ...
(Date:4/15/2014)... medical mystery and in the process have found a potentially ... 1.5 million people a year. The researchers say they now understand ... been in use for more than 50 years even though ... to the microbes it attacks. , A report of ...
(Date:4/14/2014)... been made in chemotherapy over the past decade, but ... continues to be a major challenge. , Nanotechnology ... the use of nanocarriers, or capsules, that can transport ... body. , The catch? These carriers are tiny, and ...
Breaking Medicine News(10 mins):Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Nano shake-up 2
... WILMINGTON, Delaware, September 2 According to a ... by MarketsandMarkets,( http://www.marketsandmarkets.com ), the global emerging lighting technologies,market ... recording an,estimated CAGR of 7.9% from 2009 to 2014. ... 39% of the total revenues. , ...
... , , SAN JOSE, Calif., Sept. ... company, today announced that its IsoFlow (TM) infusion ... Drug Administration (FDA) for the direct delivery of medications into highly ... treatment of cancer. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090902/SF69552 ) ...
... What you need to know about vaccinations for swine flu, ... fall, Americans will face a double challenge in getting shots ... and the seasonal variety. , "Two different vaccines are ... Hay, an assistant professor of medicine at the University of ...
... , , , LA JOLLA, ... today announced that Dr. Juliet Singh, President and Chief Executive Officer ... Partners Healthcare Conference in Boston, MA on Wednesday, September 9, 2009 ... can access a live audio webcast via the Internet by visiting ...
... , , WASHINGTON, Sept. 2 Danaher ... has signed a definitive agreement with MDS Inc. (TSX: MDS; ... division of MDS, which includes a 50% ownership position in ... business, and a 100% ownership position in the former Molecular ...
... , , MOUNTAIN VIEW, Calif., Sept. ... it will participate in the following events in September: , , ... Friday, September 11, at 10:20 a.m. ET in Boston, ... 13, in Philadelphia, Late-Breaking oral platform presentation on Saturday, September ...
Cached Medicine News:Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 2Health News:MarketsandMarkets: Global Emerging Lighting Technologies Market Worth US$112.2 Billion by 2014 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 2Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 3Health News:Potential Breakthrough Cancer Treatment Now Available From Vascular Designs 4Health News:Keep Your Flu Shots Straight This Fall 2Health News:Keep Your Flu Shots Straight This Fall 3Health News:Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 2Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 3Health News:Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation 4Health News:MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences 2
Forceps, extra delicate, straight....
Jewelers Forceps, delicate, straight....
Cilia Forceps, slanted jaws, gold plated....
1 mm x 6 mm oval hole....
Medicine Products: